What is the 13F Pro Quality Score for XBIO?

13F Pro ranks Xenetic Biosciences, Inc. (XBIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XBIO's current score at https://13fpro.ai/research/XBIO (free sign-up required for the full ranking).

Where does 13F Pro source XBIO data?

All Xenetic Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Xenetic Biosciences, Inc. files with the SEC under CIK 1534525. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XBIO in?

Xenetic Biosciences, Inc. (XBIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XBIO research updated on 13F Pro?

XBIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Xenetic Biosciences, Inc.(XBIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1534525 XBIO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $7.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

XBIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Xenetic Biosciences, Inc. (XBIO), a Healthcare sector company. XBIO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $7.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Xenetic Biosciences, Inc. reports quarterly revenue of $806.9K, net income of $-456.4K, free cash flow of $-536.4K. Top institutional holders of XBIO by reported 13-F value include RENAISSANCE TECHNOLOGIES, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XBIO trades on the Nasdaq exchange and files with the SEC under CIK 1534525. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xenetic Biosciences, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$806.9K

Net Income

Q1 2026

$-456.4K

Free Cash Flow

Q1 2026

$-536.4K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+19.0% YoY

$3.0MFY 2025

FY21 $1.2MFY22 $1.7MFY24 $2.5MFY25 $3.0M

Net Income

+32.3% YoY

$-2.7MFY 2025

FY21 $-5.6MFY22 $-6.6MFY24 $-4.0MFY25 $-2.7M

Operating Income

+32.6% YoY

$-2.8MFY 2025

FY21 $-5.7MFY22 $-6.7MFY24 $-4.2MFY25 $-2.8M

EPS (Diluted)

+38.5% YoY

$-1.58FY 2025

FY21 $-0.06FY22 $-0.46FY24 $-2.57FY25 $-1.58

Total Assets

+21.2% YoY

$8.4MFY 2025

FY21 $19.8MFY22 $14.7MFY24 $6.9MFY25 $8.4M

Op. Cash Flow

+18.8% YoY

$-2.3MFY 2025

FY21 $-4.7MFY22 $-4.6MFY24 $-2.8MFY25 $-2.3M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2019	FY 2017
Revenue	$3.0M +19.0%	$2.5M +46.5%	$1.7M +47.1%	$1.2M +6701.2%	$17.1K -99.8%	$7.6M
Net Income	$-2.7M +32.3%	$-4.0M +39.6%	$-6.6M -16.1%	$-5.6M +55.8%	$-12.8M -255.3%	$-3.6M
Operating Income	$-2.8M +32.6%	$-4.2M +37.4%	$-6.7M -16.9%	$-5.7M +55.4%	$-12.9M -261.1%	$-3.6M
EPS (Diluted)	$-1.58 +38.5%	$-2.57 -457.5%	$-0.46 -738.2%	$-0.06	—	—
Total Assets	$8.4M +21.2%	$6.9M -53.1%	$14.7M -25.7%	$19.8M -8.0%	$21.5M +12.4%	$19.2M
Operating Cash Flow	$-2.3M +18.8%	$-2.8M +39.4%	$-4.6M +1.9%	$-4.7M +26.0%	$-6.4M -528.3%	$1.5M

AI Insight: XBIO Financial Trends

Xenetic remains pre-revenue with persistent operating losses and equity erosion, though Q4 2025 showed modest cash-burn improvement.

• Revenue flat at $1M across all 8 quarters; operating losses consistent at $0–1M per quarter with no scale.

• Equity declined from $7M (Q2 2024) to $4M (Q3 2025), recovering to $7M by Q1 2026; cumulative shareholder value erosion.

• Operating cash flow improved to $0M in Q2 2025 and Q4 2025 versus $−1M baseline; burn moderated but not eliminated.

⚠ No debt reported; reliance on equity financing and cash reserves to fund operations amid zero revenue growth.

⚠ Q1 2026 operating cash burn returned to −$1M after two quarters of zero burn; sustainability of cash position unclear.

AI Insight: XBIO Ratio Trends

Operating margin improved 12.8pp from Q4 2025 to Q1 2026, but company remains deeply unprofitable with negative ROIC across all periods.

• OpMargin improved from -81.3% in Q4 2025 to -62.2% in Q1 2026, narrowing losses sequentially.

• ROE and ROA both improved in Q1 2026 versus Q4 2025, suggesting reduced shareholder value destruction.

• All profitability metrics remain deeply negative; ROIC has never exceeded -28.4% across nine periods.

⚠ Q3 2025 showed strongest OpMargin (-53.0%), but deteriorated again in Q4 2025 (-81.3%). Volatility suggests operational instability.

⚠ TTM OpMargin of -75.0% masks recent modest improvements. Monitor whether Q1 2026 trend toward profitability sustains.

Get alerted when XBIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Xenetic Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XBIO

RENAISSANCE TECHNOLOGIES LLC
$368.3K137,440 sh
GEODE CAPITAL MANAGEMENT, LLC
$57.5K21,441 sh
VANGUARD CAPITAL MANAGEMENT LLC
$18.0K6,731 sh
Tower Research Capital LLC (TRC)
$2.2K806 sh
JTC Employer Solutions Trusteee Ltd
$7.002,700 sh
Darwin Wealth Management, LLC
$5.002 sh

Fund	Value	Shares
RENAISSANCE TECHNOLOGIES LLC	$368.3K	137,440
GEODE CAPITAL MANAGEMENT, LLC	$57.5K	21,441
VANGUARD CAPITAL MANAGEMENT LLC	$18.0K	6,731
Tower Research Capital LLC (TRC)	$2.2K	806
JTC Employer Solutions Trusteee Ltd	$7.00	2,700
Darwin Wealth Management, LLC	$5.00	2

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XBIO on your watchlist

Track score changes the day Xenetic Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XBIO a good stock to buy?

13F Pro's AI-powered analysis of Xenetic Biosciences, Inc. (XBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XBIO are available on the XBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XBIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Xenetic Biosciences, Inc.'s investment landscape.